16 Jan The long-term impact of COVID-19 on clinical trials: Part 2
By James Gillespie, John Whyte, and Greg Licholai, Clinical Leader
The COVID-19 pandemic is helping create a “new normal” for the life sciences industry regarding the policies, procedures, and processes of clinical trials. This is accelerating the pace of change and fundamentally altering the interface of biopharmaceutical companies with patients, providers, regulators, and other key stakeholders. In continuing our analysis, we focus here on broader organizational and sector level dynamic such as competitor collaboration, globalization, industry goodwill, public health, supply chain, and workplace environment. Read more …